Author: NSV
Ventyx Biosciences announces positive results from the Phase 2 trial of VTX002 in patients with moderate-to-severely active ulcerative colitis
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced positive results from the Phase 2 trial of VTX002, a novel oral S1P1 receptor modulator, in patients with moderate-to-severely
Read More
Glydways announces $56 Million Series B Round with New Science Ventures, ACS Group, Khosla Ventures and Gates Frontier
Glydways, a leader in developing on-demand Personal Rapid Transit (PRT), has announced its $56 million Series B round, including the conversion of notes valued at more than $28 million and led by New Science Ventures with participation from The ACS Group and Gates Frontier. Khosla Ventures, Glydways first investor, is
Read More
Paragraf named Business of the Year in Cambridge glory parade
Paragraf, the first company in the world to mass produce graphene-based electronic devices using standard semiconductors processes, was named Business of the Year in the 33rd annual Business Weekly Awards on 14 September 2023. Co-founders Simon Thomas – the CEO – and CSO Professor Sir Colin Humphreys received the coveted
Read More
Zeotap and Artefact join forces to enhance economic outcomes for enterprises with Customer Data Platform
Zeotap CDP, the easy, secure and impactful Customer Data Platform (CDP) has established a strategic partnership with Artefact, a global data consulting service specialist. This collaboration will help to deliver effective data-driven marketing while prioritising consumer privacy and security. Enterprises will benefit from a holistic and integrated approach that will
Read MoreVentyx Biosciences announces initiation of dosing in a Phase 1 trial of VTX3232, a novel CNS-penetrant NLRP3 inhibitor
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that the first subject has been dosed in a Phase 1 trial of VTX3232, a novel central nervous system
Read MoreVentyx Biosciences announces completion of enrollment of the Phase 2 trial of VTX002 in ulcerative colitis and the Phase 2 trial of VTX958 in plaque psoriasis
Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that the Company has completed patient enrollment in the Phase 2 trial of VTX002 in ulcerative colitis and the
Read More
Trellis Bioscience announces positive interim Phase 1 results for TRL1068, a novel native human monoclonal antibody which reduces bacterial biofilm burden in chronic prosthetic joint infections
Trellis Bioscience Inc, a clinical stage privately held biotechnology company focused on the discovery and development of native human monoclonal antibodies, has announced a clinical proof-of-concept milestone from a planned interim analysis of the company's Phase 1 trial of its lead antibody, TRL1068 (calpurbatug), in patients with prosthetic joint infections
Read MoreParagraf acquires Cardea Bio to extend graphene electronics leadership
Paragraf, the only company in the world to mass produce graphene electronics using transfer-free graphene and standard semiconductor processes, has acquired Cardea Bio, the world’s leading producer of graphene-based biocompatible chips. Cardea Bio is to be renamed Paragraf USA and the San Diego facility, team and operations have already become
Read More
Picocom and Antevia Networks collaborate to provide new innovative 5G in-building solutions for enterprise private networks
Picocom, the 5G Open RAN baseband semiconductor and software specialist, has announced Antevia Networks has selected Picocom’s award-winning silicon technology to empower its new innovative 5G in-building solutions. The partnership combines Antevia Networks’ technology with Picocom’s latest generation 5G system-on-chip silicon to drive innovations to address the many challenges of
Read More
Isorg collaborates with Precise Biometrics on turnkey fingerprint sensor solution for smartphone industry
Isorg, a pioneer in Organic PhotoDetectors (OPDs) and large area image sensors, announces further details on the company’s collaboration with Precise Biometrics, a leader in fingerprint verification software, on a new Fingerprint on Display (FoD) solution for the mobile industry. While increasing resolution unquestionably remains a major trend within the
Read MoreIsorg’s FAP30 optical fingerprint sensor obtains FBI certification
Isorg, a pioneer in Organic PhotoDetectors (OPDs) and large area image sensors, has announced the FBI certification of Bio1Print30, a large-area optical fingerprint sensor for applications where enhanced mobile security and nomad ID authentication are key. The Bio1Print30, a FAP30 (Fingerprint Acquisition Profile) device, whose core technology is compatible with
Read More
NorthSea Therapeutics provides clinical update reflecting progress across NASH and metabolic disorders programmes
NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, has provided an update on its clinical pipeline of structurally engineered fatty acids (‘SEFAs’), a new class of fatty acids drugs, for the treatment
Read More